EFFICACY OF MONOTHERAPY WITH ADX10059, A MGLUR5 NEGATIVE ALLOSTERIC MODULATOR, FOR CLINICAL SYMPTOM CONTROL IN PATIENTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)

(1) CHU Bordeaux, Hôipital Saint André, Dept. of Gastroenterology, Bordeaux, France

(2) Gastroenterology, CHU Nantes, Nantes, France

(3) Gastroenterology, CHU Lyon, Lyon, France

(4) Gastroenterology, KU Leuven, Leuven, Belgium

(5) Gastroenterology, Otto vonGuericke University, Magdeburg, Germany

(6) ADDEX Pharma Medical, Plan les Ouates, Switzerland



This item was part of the Oesophageal, Gastric and Duodenal Disorders II session at UEG Week Barcelona 2010

This item can be cited as: Gut 2010; 59 (Suppl III) A232